WO2001003742A1 - Composition de medicament pour administration topique - Google Patents
Composition de medicament pour administration topique Download PDFInfo
- Publication number
- WO2001003742A1 WO2001003742A1 PCT/JP2000/004651 JP0004651W WO0103742A1 WO 2001003742 A1 WO2001003742 A1 WO 2001003742A1 JP 0004651 W JP0004651 W JP 0004651W WO 0103742 A1 WO0103742 A1 WO 0103742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- topical administration
- pharmaceutical composition
- insoluble polymer
- base
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention relates to a technique for topically administering an active ingredient, specifically, a soft gel that is suitable for administration before topical application, and hardens after application to elongate the topical active ingredient.
- the present invention relates to a pharmaceutical preparation base that can be maintained for a long period of time, and a pharmaceutical composition for topical administration prepared by using the base and having controlled drug release.
- plasters containing various antibiotics as main components include aminoglycosides, tetracyclines and chloramphenicol, etc., and dermatology, ophthalmology, ENT, dental and oral surgery, urology. It is widely used for inflammatory and purulent diseases related to gynecology and gynecology.
- kanamycin sulfate ointment which is an aminoglycoside antibiotic
- tetracycline hydrochloride ointment which is a tetracycline antibiotic
- chloramphenicol ointment which is a chloramphenicol antibiotic
- Ophthalmic ointment of pimaricin, a macrolide antibiotic is also marketed as an agent.
- An ointment containing the tetracycline antibiotics tetracycline hydrochloride and hydrocortisone acetate is marketed for dental use.
- Ointments require that the active ingredient be stably incorporated into a pharmaceutical composition.
- one of tetracycline-based minocycline or a pharmaceutically acceptable salt thereof is required. Salt from water-soluble polymer and polyhydric alcohol
- a pharmaceutical composition for topical administration in which a magnesium compound is blended with a magnesium compound to stabilize an antibiotic, is used for the treatment of periodontal disease for topical administration.
- Polyhydric alcohols eg, glycerin
- water-soluble polymeric substances eg, hydroxyethyl cellulose
- certain methacrylic acid-based copolymers eg, aminoalkyl methacrylate
- Polymer RS polymer RS
- its solubilizing agent for example, triacetin
- Japanese Patent Application Laid-Open No. 7-89874 describes a hydrophobic ointment base (for example, plastic base), a polyhydric alcohol (for example, propylene glycol), an adhesive substance (for example, hydroxypropyl methylcellulose).
- sustained-release oral ointment characterized by containing a metal compound (for example, aluminum aluminum hydroxide) containing aluminum and an active ingredient and an active ingredient.
- a metal compound for example, aluminum aluminum hydroxide
- This ointment can be applied to the periodontal pocket and is intended to increase the utilization rate of the active ingredient while maintaining a sufficient concentration of the active ingredient in the strength, strength and affected area for a long period of time.
- the present inventors have obtained the idea that, in order to release the active ingredient stably and for a long period of time, it is necessary to impart shape retention after application to the composition.
- a curable preparation for topical administration was developed, and the present invention was completed.
- at least the surface part is hardened at the applied local area,
- a pharmaceutical base capable of retaining the effect of an active ingredient by staying locally for a long period of time particularly a pharmaceutical base for topical administration, typically a pharmaceutical base for oral administration.
- the present invention is directed to a topical administration method comprising mixing an active ingredient with the above-mentioned base, and hardening at least partially on the surface after application, staying locally for a long time and maintaining the effect of the active ingredient for a long time. And a preparation for oral administration.
- the present invention provides an active ingredient for treating periodontal disease which is added to the above-mentioned base.
- the gel-like force is applied so that it can be easily applied before application to periodontal pockets.
- an ointment for oral administration in which a part is hardened and stays in a periodontal pocket for a long period of time to maintain the effect of the active ingredient.
- Fig. 1 shows a test to evaluate how the hardness of the locally applied base material of the present invention changes.
- the base material at the start of the test (0 hour immersion in purified water) was treated with rheometer.
- 5 is a graph showing the results measured in Example 2 (Example 2).
- Figure 2 shows a rheometer of a base immersed in purified water at 37 ° C for 24 hours in a test to determine how the hardness of the topically applied base of the present invention changes.
- 5 is a graph showing measurement results (Example 2).
- Figure 3 shows a rheometer of a base immersed in purified water at 37 ° C for 48 hours in a test to evaluate how the hardness of the base of the present invention applied topically changes.
- 5 is a graph showing the results measured in Example 2 (Example 2).
- FIG. 4 is a photograph showing the result of examining good retention of the base of the present invention in agar gel (Example 3). Detailed description of the invention
- the base of the present invention comprises a water-insoluble polymer, a solvent in which the water-insoluble polymer is dissolved and has compatibility with water as essential components, and other additives as necessary. .
- the base is usually in the form of a soft gel, cream or ointment at the fingertips, by a tube or by a specially designed injection device such as a syringe. It can be easily applied locally (eg, periodontal pocket). Solvents that are compatible with water allow the water present around the application site as it escapes from the base to penetrate at least the surface portion of the base. Due to the infiltration of water, the water-insoluble polymer hardens at least on the surface of the base material.
- the cured base may be elastic in some cases.
- the base is cured by curing and, in some cases, being more elastic, so that the applied base and the active ingredients contained therein can be physically The inconvenience of being washed away by force is prevented, and the release of the active ingredient into the tissue can be controlled.
- water-insoluble polymer used in the present invention examples include aminoalkyl methacrylate copolymer RS, aminoalkyl methacrylate copolymer E, methyl methacrylate copolymer L, methacrylate copolymer S, and ethyl cellulose.
- a water-insoluble polymer that can be used as an additional component of the active ingredient can be appropriately selected and used.
- the water-insoluble polymer in the base or the compounding amount thereof is appropriately selected so as to be dissolved in a solvent and form a gel when combined with the solvent.
- a solvent typically about 5 to 40% by weight of the total composition, and considering the dosage form using a syringe, Particularly, about 10 to 30% by weight is preferable.
- solvents that dissolve the water-insoluble polymer and are compatible with water are: triethyl citrate, triacetin, tributyrin, diacetyl ethylene glycol, getyl sebacate, getyl phthalate, dibutyl phthalate, ethylene glycol. Or one or more selected from the group consisting of diethylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol, glycerin and acetylglycerin fatty acid ester.
- the solvent is not limited to these, and a solvent that can be used as an additive component of the active ingredient can be appropriately selected and used.
- the solvent and the amount of the solvent in the base are appropriately selected so as to form a gel when combined with the water-insoluble polymer. Taking into account the viscosity and fluidity that affect handling during use and manufacture, typically about 30-95% by weight of the total composition, taking into account dosage forms using syringes Is particularly preferably about 40 to 70% by weight.
- the base of the present invention may contain other additives commonly used in the field of pharmaceuticals. Those skilled in the art can determine the types and amounts of such additives as needed. Examples of additives include pH adjusters (eg, organic acids such as adipic acid and fumaric acid, and inorganic salts such as phosphates) for improving the stability of the active ingredient and the local solubility of the active ingredient.
- pH adjusters eg, organic acids such as adipic acid and fumaric acid, and inorganic salts such as phosphates
- a chelating agent such as ethylenediaminetetraacetate sodium nitrate
- an adhesive for improving the retentivity to an applied tissue eg, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose
- Pullulan carboxyvinyl polymer, sodium alginate, psyllium gum, gelatin, agar, carrageenan, dextrin
- swelling agents eg, low-substituted hydroxypropylcellulose, carboxymethylcellulose calcium, carboxymethyl
- Fats and oils for example, paraffin, carnauba wax, rapeseed oil, olive oil, orange oil, eucalyptus oil, seaweed oil, wheat germ oil, cocoa butter, sesame oil, salami beeswax, white petrolatum, crystallin wax ), Fatty acids and derivatives such as salts and esters thereof (eg, stearic acid, medium-chain fatty acid triglyceride, hard fat, calcium stearate, aluminum stearate, isopropyl myristate), surface active agents (eg, Sucrose fatty acid ester, lauromacrogol, setoma Clogol, glyceryl monostearate, sorbitan monolaurate, monono, sorbitan lumitate, sorbitan trioleate, sorbitan sesquioleate, polyoxyethylene hard castor oil, polyoxyl stearate), polyhydric alcohols and higher alcohols For example, polyethylene glycol, propylene glycol
- the physical properties of the formulation and the Stearic acid and stearyl alcohol are particularly preferred from the viewpoint of release.
- fats and oils are blended as an additive, those which are compatible with the solvent used are preferred. Fats and oils that are solid at room temperature are heated, dissolved in a solvent, cooled and used.
- the compounding amount of the above additives is appropriately set in view of the physical properties and release properties required for the preparation or the base for the preparation.
- the base of the present invention When the base of the present invention is used for preparing a composition for intraoral administration, it is insoluble or hardly soluble in a solvent in order to improve physical properties such as viscosity and spinnability before topical application in the oral cavity. May be blended.
- a solvent in order to improve physical properties such as viscosity and spinnability before topical application in the oral cavity. May be blended.
- examples are polyethylene powder, hydrogenated vegetable oil powder, talc, magnesium stearate, sugar alcohols, anhydrous silicon dioxide, calcium hydrogen phosphate, carnauba wax, kaolin, synthetic aluminum gayate, titanium oxide, calcium carbonate, and bentonite. From the viewpoints of the physical properties of the preparation and the release of the active ingredient, polyethylene powder, dandelion vegetable oil powder and carnauparow are particularly preferred.
- the additive powder insoluble in a solvent or the compounding amount thereof is appropriately selected in order to improve physical properties such as handling in production, viscosity before application to an oral cavity, and spinnability.
- a typical amount is about 5 to 50% by weight based on the whole composition.
- the specific gravity of the solvent used is preferably in the range of 0.5 to 1.5, and the particle diameter is 100 // m or less. Is preferably 10 ⁇ or less.
- the present invention is manufactured by blending an active ingredient with the above-mentioned base, and before application, is applied to a gel or plaster-like topical part, and then the surface part is rapidly cured, and
- the present invention also provides a pharmaceutical composition or an ointment preparation for topical administration, which stays for a long time and gradually releases the active ingredient locally.
- the pharmaceutical composition for topical administration of the present invention is not particularly limited in its scope of application, for example, ophthalmology (ocular mucosa), otolaryngology (intranasal, oral), dentistry (periodontal disease, caries, etc.) , Oral Surgery (pre-operative and post-operative procedures, etc.), Gynecology (intravaginal), Gastroenterology (in rectum), Urology, Dermatology, and Plastic Surgery (wound, decubitus, etc.) Can be used locally. Moreover, it can be used for the same purpose as veterinary medicine.
- the amount of the active ingredient may be appropriately determined in order to obtain the desired effect, but the preferred range is about 0.001% by weight to about 3% by weight based on the whole base. 0% by weight, more preferably from about 0.01% to about 10% by weight.
- the active ingredient can be dissolved, dispersed or suspended in a solvent.
- the active ingredient may be dissolved in the selected solvent and incorporated into the base.If it is not sufficiently dissolved in the solvent, the active ingredient is combined with the base as fine powder or dispersed or suspended in the solvent. May be.
- the active ingredient can be blended as fine powder, dispersion or suspension depending on the production method or application method.
- the raw material must be mixed with the base in the manufacturing process before kneading with the base.
- the drug may be used to pulverize the drug to reduce the particle size, or may be used by dissolving it in a certain solvent.
- the particle diameter of the active ingredient is not particularly limited, but is preferably about 1 m to about 500 // m. In the handling of the manufacturing process, and more preferably about 10 ⁇ m to about 2 m. 0 m.
- the active ingredient may be pretreated and blended if necessary for controlling the rate of release into tissues and improving stability.
- Examples include coating treatments, micro-compacting, adsorption to porous materials, and adsorption to ion exchange resins. These techniques are well known in the formulation art.
- the pharmaceutical composition for topical administration of the present invention comprises an antibiotic preparation, an antibacterial agent, an antifungal agent, an antiviral agent, a bactericide, an anti-inflammatory agent, a local anesthetic, a vasoconstrictor, a steroid hormone agent, an antihistamine. Agent, prostaglandin preparation or antipruritic.
- the active ingredients that can be added to them are not particularly limited. Examples of active ingredients include antibiotics such as / 3 lactams such as ampicillin, aminoglycosides such as kanamycin sulfate, tetracyclines such as tetracycline hydrochloride and minocycline, and polypeptides such as polymyxin B sulfate.
- Antibiotics such as macrolides such as clarithromycin and chloramphenicols such as chloramphenicol are blended.
- Antibacterial agents include synthetic antibacterial agents such as new quinoline-sulfamethoxazole / trimethoprim combination such as tosfloxacin tosylate.
- Antifungal agents include polyene macrolides such as amphotericin Or an azole compound.
- the antiviral agent is formulated with acyclovir divinyl rapine and the like. Cetylpyridinium chloride / povidone chloride and the like are mixed with the fungicide.
- the anti-inflammatory agent may be blended with dicillum glycyrrhizinate or lysozyme lysozyme.
- Local anesthetics include lidocaine and dibuforce hydrochloride.
- Vasoconstrictors include naphazoline hydrochloride and d1-methylefedrine hydrochloride.
- Steroid hormone preparations include hydrocortisone butyrate and the like, and antihistamines include diphenhydramine hydrochloride and chlorpheniramine maleate.
- Prostaglandin preparations include dinoprost and dinoprostone. Crotamiton and the like are compounded in the antipruritic.
- compositions alone for the treatment or prevention of diseases in ophthalmology, otorhinolaryngology, dentistry, oral surgery, gynecology, gastroenterology, dermatology, urology, plastic surgery, etc., or 2 More than one kind can be blended and used.
- Penem-based compounds are unnatural S-lactam compounds designed based on the concept of fusing the structures of penicillin and cephalosporin (eg, Woodward, RB, In Recent Ad). varices in the Chemistry of ⁇ -Lactam Antibiotics; Elks, J., Ed; The Chemical Society; London, 1977; Spec.No. 28, 167-180, JP-A-62077387, JP-A-63-162694 JP-A-60-222486 and JP-A-54-119486), a broad antibacterial spectrum and high safety possessed by ⁇ -lactam antibiotics such as penicillin antibiotics and septum antibiotics.
- ⁇ -lactam antibiotics such as penicillin antibiotics and septum antibiotics.
- the base of the present invention which comprises a water-insoluble polymer and a solvent that dissolves in the water-insoluble polymer and is compatible with water, as essential components, has a long-term stability as a suspension or dispersion of a penem compound. It was also found that it could be kept.
- the pharmaceutical composition for topical administration of the present invention is in a plaster or gel form, and can be administered using a syringe or the like. After administration, this product forms a water-insoluble film on the surface with leaching of the contained solvent and / or absorption of water, and eventually the whole product hardens and retains its shape, and stays locally for a long time. The dwell period can be designed over several weeks. Therefore, the composition of the present invention is suitable for designing a sustained-release preparation which gradually releases the contained active ingredient and maintains the active ingredient concentration locally for a long period of time.
- Example 1 Example 1
- Example 1 The following bases and formulations were prepared. The composition of each composition is shown in Table 1, Table 2, Table 4, Table 5, or Table 7.
- Aminoalkyl methacrylate copolymer RS (trade name Eudragit RS, was dissolved in triethyl citrate by heating at 90 ° C, allowed to cool to room temperature, and then defoamed under reduced pressure to obtain a composition.
- Aminoalkyl methacrylate copolymer RS was dissolved in triethyl citrate by heating at 90 ° C and allowed to cool to room temperature.Polyethylene powder was added, mixed uniformly, and defoamed under reduced pressure to obtain a composition. .
- Aminoalkyl methacrylate copolymer RS was dissolved in triethyl citrate by heating at 90 ° C, allowed to cool to room temperature, added with Food Blue No. 1, mixed uniformly, and defoamed under reduced pressure to obtain a composition.
- Food Blue No. 1 was added with Food Blue No. 1, mixed uniformly, and defoamed under reduced pressure to obtain a composition.
- Aminoalkyl methacrylate copolymer RS is dissolved in triethyl citrate by heating at 90 ° C and allowed to cool to room temperature.After adding Food Blue No. 1 and polyethylene powder to mix uniformly, defoam under reduced pressure A composition was obtained.
- the ethylcellulose was dissolved in triethyl citrate by heating at 90 ° C, and stealyl alcohol was added while heating and mixed uniformly. After allowing to cool to room temperature, Edible Blue No. 1 was added and uniformly mixed, followed by defoaming under reduced pressure to obtain a composition.
- Hydroxyethyl cellulose and magnesium chloride (hexahydrate) were dispersed in glycerin and dissolved by heating to 100 ° C. After dissolution, the mixture was cooled to 50 ° C to obtain a mixture. On the other hand, a solution was prepared by dissolving aminoalkyl methacrylate copolymer R-S in triacetin, and this was added to the above-mentioned mixture and uniformly mixed to obtain a composition.
- Plastibase, aluminum hydroxide, propylene glycol and hydroxypropyl methylcellulose were uniformly mixed to obtain a composition.
- a formulation was prepared by mixing an appropriate amount of Food Blue No. 1 with Comparative Base Example 1. Hydroxyl cellulose and magnesium chloride (hexahydrate) are dispersed in glycerin, To dissolve. After dissolution, the mixture was cooled to 50 ° C to obtain a mixture. On the other hand, a solution was prepared by dissolving the aminoalkyl methacrylate copolymer RS in triacetin, and this solution and Edible Blue No. 1 were added to the above mixture and uniformly mixed to obtain a composition.
- a formulation was prepared by mixing an appropriate amount of Food Blue No. 1 with Comparative Base Example 2. Plastibase, aluminum hydroxide, propylene glycol, hydroxypropylmethyl cellulose and Edible Blue No. 1 were uniformly mixed to obtain a composition.
- Aminoalkyl methacrylate copolymer RS is dissolved in triethyl citrate by heating at 90 °, allowed to cool to room temperature, added with minocycline hydrochloride and polyethylene powder, mixed uniformly, and then defoamed under reduced pressure to form a composition. I got something.
- the minocycline hydrochloride used passed through No. 100 of the Japanese standard sieve and remained in No. 200.
- Hydroxyethyl cellulose and magnesium chloride (hexahydrate) were dispersed in glycerin and dissolved by heating to 100 ° C. After dissolution, the mixture was cooled to 50 ° C, minocycline hydrochloride was added, and the mixture was uniformly dissolved to obtain a mixture. On the other hand, a solution was prepared by dissolving the aminoalkyl methacrylate copolymer RS in triacetin, and the solution was added to the mixture and uniformly mixed to obtain a composition.
- Rinominoalkyl methacrylate copolymer was added to triethyl citrate 90. After heating and dissolving with C, the mixture was allowed to cool to room temperature, and then mixed with water and polyethylene powder, and then defoamed under reduced pressure to obtain a composition. It should be noted that the farovene sodium used was one that passed through No. 100 standard sieve and remained in No. 200.
- the ethyl cellulose was heated and dissolved in triethyl citrate at 90 ° C., allowed to cool to room temperature, added with farobenem sodium and polyethylene powder, mixed uniformly, and then defoamed under reduced pressure to obtain a composition.
- the faropenem sodium used passed the No. 100 standard sieve in Japan and remained in No. 200. '
- Formulation Example 4 The aminoalkyl methacrylate copolymer RS and ethyl cellulose were heated and dissolved in triethyl citrate at 90 ° C. and allowed to cool to room temperature, and then Venaena sodium and polyethylene powder were added and uniformly mixed. The composition was defoamed under reduced pressure to obtain a composition.
- the faropenem sodium used passed the No. 100 standard sieve of the Japanese Pharmacopoeia and remained in the No. 200 sieve.
- Aminoalkyl methacrylate copolymer RS is dissolved in triacetin by heating at 90 ° C and allowed to cool to room temperature.Farovenem sodium and polyethylene powder are added, and the mixture is mixed uniformly, followed by defoaming under reduced pressure. I got something. The farovene sodium used was that which passed through No. 100 of the Japanese standard sieve and remained in No. 200.
- Ethylcellulose was dissolved in triethyl citrate by heating at 90 ° C, and stearic acid was added while heating and mixed uniformly. After allowing to cool to room temperature, faropenem sodium was added and uniformly mixed, followed by defoaming under reduced pressure to obtain a composition.
- the farovenemum used was that which passed through No. 100 of the Japanese Pharmacopoeia standard sieve and remained in No. 200.
- Ethylcellulose was dissolved in triethyl citrate by heating at 90 ° C, and stearyl alcohol was added while heating and mixed uniformly. After allowing to cool to room temperature, faropenum sodium was added and mixed uniformly, followed by defoaming under reduced pressure to obtain a composition.
- the faropenem sodium used passed through No. 100 of the Japanese standard sieve and remained in No. 200.
- the base of the present invention is characterized in that it hardens with the lapse of time due to the outflow of a solvent and the infiltration of water after administration, so as to have a residence property at the administration site. Therefore, the hardness of the base applied locally was evaluated with a rheometer using a model.
- a cylindrical bottle having a diameter of 10.0 and a depth of 5.0 mm was filled with the base material, and left standing at 37 ° C in purified water.
- each base was plunged with a rheometer (NRM-302D, manufactured by Fudo Kogyo Co., Ltd.). (Needle tip diameter: 4.0 mm0) 20 recitations / min speed And the stress over time was measured.
- Tables 1 and 2 show the formulation of the base used in the test. When the base is hardened when the base is hardened at a constant speed, an inflection point is observed in the stress when the base is broken.
- Table 3 and FIGS. 1 to 3 show the stress at this point as the maximum elastic stress (g) and the penetration distance as the elastic limit distance (mm).
- Plastibase 79.89 9 Aluminum hydroxide 2.76 Propylene glycol 2.04 Hydroxypropyl methylcellulose 1 5.3 1
- the base of the present invention When the base of the present invention is applied locally such as in a periodontal pocket, at least the surface portion of the base is hardened, and the shape of the base during application can be maintained for a long time.
- the following tests were performed to confirm this property.
- a 2% agar gel with a slit of 1 Omm in width and 2 Omm in depth was used as a paddle of the periodontal pocket.
- Width 5 mm x length 3 OIIX 0.02 mm thick plastic piece about 1 Omg applied to the tip of the plastic piece, 2% agar gel width 1 OMI depth 20 slits Was inserted.
- the agar gel was stored in a thermostat at 37 ° C, and after leaving for a certain period of time, a piece of plastic was extracted, and the shape retention of a base containing an edible dye instead of the active ingredient was confirmed.
- Table 4 shows the formulation of the base used in the test.
- the drug release rates from the formulations of Formulation Examples 1 to 7 were confirmed by the inVitro method.
- a test was performed using a model of periodontal pocket to confirm the release rate of the drug at the administration site. More specifically, the composition filled in a syringe having an inner diameter of 300 at the tip is approximately 1 round on the tip of a plastic piece having a width of 5 faces, a length of 30 mm and a thickness of 0.02 mm.
- O mg was precisely measured and applied, and inserted into a 2 mm agar gel provided with a 10 mm wide, 2 mm deep Orain slit. This agar gel was stored in a thermostat at 37 ° C, and after a certain period of time, a piece of plastic was extracted, and the amount of drug remaining in the preparation was determined.
- Analytical conditions for minocycline hydrochloride A high performance liquid chromatography column made of stainless steel and filled with octadecyl silylated silylation gel was used. Column temperature was set at 40 ° C. As the mobile phase, a solution prepared by dissolving 20.2 g of triethylamine in a water / acetonitrile mixture (100 ml: 50 ml) and adjusting the pH to 2.2 by adding phosphoric acid was used. The flow rate was adjusted so that the retention time of minocycline hydrochloride was about 14 minutes. An ultraviolet absorption spectrophotometer was used as a detector, and a measurement wavelength of 354 nm was used.
- Tables 5 and 7 show the formulations of the formulations used in the analysis, and Tables 6 and 8 show the corresponding analysis results.
- Formulation Example 2 Formulation 7 Ingredients Formulation Example 2 Formulation Example 3 Formulation Example 4 Formulation Example 5 Formulation Example 6 Formulation Example 7 Phallopenem sodium 2 2 2 2 2 2 2 Techinoresenorelose 14 7 16 16 Aminoalkylmethacrylate
- Stearyl alcohol 20 Total 100 100 100 100 100 100 100 100 100
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020017003170A KR20010075053A (ko) | 1999-07-12 | 2000-07-12 | 국소 투여용 의약 조성물 |
EP00946272A EP1112750A1 (en) | 1999-07-12 | 2000-07-12 | Drug composition for topical administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/198012 | 1999-07-12 | ||
JP19801299 | 1999-07-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09786815 A-371-Of-International | 2001-06-25 | ||
US10/750,947 Continuation US20040208906A1 (en) | 1999-07-12 | 2004-01-05 | Pharmaceutical composition for topical administration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001003742A1 true WO2001003742A1 (fr) | 2001-01-18 |
Family
ID=16384052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004651 WO2001003742A1 (fr) | 1999-07-12 | 2000-07-12 | Composition de medicament pour administration topique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1112750A1 (ja) |
KR (1) | KR20010075053A (ja) |
CN (1) | CN1320046A (ja) |
WO (1) | WO2001003742A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509910A (ja) * | 2000-09-26 | 2004-04-02 | トーマス・アール・パタッカ | 歯被覆組成物 |
JP2016500095A (ja) * | 2012-11-27 | 2016-01-07 | ホビオネ サイエンティア リミテッド | テトラサイクリン局所製剤、その調製及び使用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1262172A1 (en) * | 2001-05-25 | 2002-12-04 | Italmed S.N.C. Di Galli G. & Pacini G. | Liquid polymer composition for prevention and treatment of the oral cavity diseases |
US7476697B2 (en) | 2001-09-10 | 2009-01-13 | Patacca Thomas R | Tooth coating composition |
US20060134012A1 (en) * | 2002-12-16 | 2006-06-22 | Symington John M | Temporary pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing |
WO2006112690A1 (en) * | 2005-04-22 | 2006-10-26 | R & H Minerals B.V. | Mineral salt gel compositions |
FR2908659B1 (fr) * | 2006-11-16 | 2011-12-02 | Univ Nantes | Vernis dentaire a liberation prolongee d'antiseptique a l'aide d'une matrice comprenant au moins un polymere methacrylique,en particulier pour patient neutropenique. |
CN101756924B (zh) * | 2008-12-24 | 2011-04-13 | 鲁南制药集团股份有限公司 | 法罗培南的缓释片 |
US11426351B2 (en) * | 2019-12-26 | 2022-08-30 | Sunstar Inc. | Process for producing a pharmaceutical composition containing micro particles |
CN111773179A (zh) * | 2020-08-07 | 2020-10-16 | 常州市第四制药厂有限公司 | 一种盐酸米诺环素软膏及制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0184389A2 (en) * | 1984-11-29 | 1986-06-11 | Sunstar Kabushiki Kaisha | Composition stably containing minocycline for treating periodontal diseases |
JPS6379817A (ja) * | 1986-09-22 | 1988-04-09 | Sunstar Inc | 歯周疾患治療用組成物 |
JPS63287719A (ja) * | 1987-05-20 | 1988-11-24 | Sunstar Inc | 歯槽骨代謝治療用組成物 |
JPH07267867A (ja) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | 抗内毒素作用を有する治療用薬剤 |
JPH07267868A (ja) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | バイオフィルム除去剤 |
-
2000
- 2000-07-12 KR KR1020017003170A patent/KR20010075053A/ko not_active Application Discontinuation
- 2000-07-12 WO PCT/JP2000/004651 patent/WO2001003742A1/ja not_active Application Discontinuation
- 2000-07-12 CN CN00801693A patent/CN1320046A/zh active Pending
- 2000-07-12 EP EP00946272A patent/EP1112750A1/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0184389A2 (en) * | 1984-11-29 | 1986-06-11 | Sunstar Kabushiki Kaisha | Composition stably containing minocycline for treating periodontal diseases |
JPS6379817A (ja) * | 1986-09-22 | 1988-04-09 | Sunstar Inc | 歯周疾患治療用組成物 |
JPS63287719A (ja) * | 1987-05-20 | 1988-11-24 | Sunstar Inc | 歯槽骨代謝治療用組成物 |
JPH07267867A (ja) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | 抗内毒素作用を有する治療用薬剤 |
JPH07267868A (ja) * | 1994-03-30 | 1995-10-17 | Sunstar Inc | バイオフィルム除去剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004509910A (ja) * | 2000-09-26 | 2004-04-02 | トーマス・アール・パタッカ | 歯被覆組成物 |
JP2016500095A (ja) * | 2012-11-27 | 2016-01-07 | ホビオネ サイエンティア リミテッド | テトラサイクリン局所製剤、その調製及び使用 |
Also Published As
Publication number | Publication date |
---|---|
EP1112750A9 (en) | 2001-09-19 |
KR20010075053A (ko) | 2001-08-09 |
CN1320046A (zh) | 2001-10-31 |
EP1112750A1 (en) | 2001-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2339069T3 (es) | Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico, un eter de celulosa y un disgregante para la fabricacion de un medicamento para tratar trastornos genitales femeninos. | |
WO1999036098A1 (fr) | Composition antibacterienne contenant des antibiotiques et destinee a l'administration topique | |
JP2001335477A (ja) | ミノサイクリン含有組成物 | |
PT1776109E (pt) | Formulação farmacêutica que compreende um antibiótico, um triazol e um corticosteróide | |
JPH0759496B2 (ja) | 歯周病治療剤 | |
EP2525789B1 (en) | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof | |
JP4449213B2 (ja) | 坐剤用組成物 | |
US20040208906A1 (en) | Pharmaceutical composition for topical administration | |
JP2022123032A (ja) | エダラボン医薬組成物 | |
JPH08253412A (ja) | ポリエチレングリコールのためのゲル化剤 | |
WO2001003742A1 (fr) | Composition de medicament pour administration topique | |
BRPI0416123B1 (pt) | composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção | |
JP2007077152A (ja) | 膣のpHを低下させるための組成物および方法 | |
US20240108603A1 (en) | Material and method for treating cancer | |
JPS63130541A (ja) | 抗菌性組成物 | |
CN104338147A (zh) | 一种用于缓控释给药的软膏组合基质 | |
CN104244983A (zh) | 控制释放组合物及其使用方法 | |
JP5324091B2 (ja) | 薬物送達のための医薬組成物及びそれを使用する症状の治療又は予防法 | |
JP2000229859A (ja) | 安定なブプレノルフィン経鼻製剤 | |
JP4500013B2 (ja) | 局所麻酔組成物 | |
WO1997029777A1 (fr) | Systeme d'administration de medicament utilisant une galactoxyloglucane | |
JP2003509367A (ja) | 粘膜炎を治療または予防するための処方物 | |
RU2201219C2 (ru) | Фармакологическая композиция пролонгированного действия | |
RU2367456C2 (ru) | Фармацевтическая композиция для местного применения, обладающая антибактериальным и некролитическим действием | |
KR20210099553A (ko) | 주사 가능한 서방형 항생 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00801693.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2001 509215 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000946272 Country of ref document: EP Ref document number: 1020017003170 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09786815 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000946272 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017003170 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017003170 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000946272 Country of ref document: EP |